Post by Hot Christian Stocks on May 12, 2012 11:54:17 GMT -5
GILD - Gilead Sciences, Inc
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need. The company’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS; liver diseases, such as hepatitis B and C; and serious cardiovascular/metabolic and respiratory conditions. It has operations in North America, Europe, and the Asia Pacific. Products HIV/AIDS Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg): Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is the once-daily single-tablet regimen for HIV intended as a therapy or in combination with other antiretrovirals. It is a fixed-dose combination of the company’s antiretroviral medications, Viread (tenofovir disoproxil fumarate) and Emtriva (emtricitabine), and Bristol Myers-Squibb Company’s (BMS) non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz). The company has collaboration with BMS to develop and commercialize the single-tablet regimen of its Truvada and BMS’s Sustiva in the United States. Under an agreement with Merck & Co., Inc. (Merck), the company promotes and distributes Atripla in 12 countries in Latin America and the Asia Pacific either through Merck or its existing third-party distributors. Truvada (emtricitabine and tenofovir disoproxil fumarate): Truvada is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of the company’s antiretroviral medications, Viread, and Emtriva. Viread: Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in patients two years of age and older. Viread is also approved for the treatment of chronic hepatitis B in adults. Complera/Eviplera: Complera/Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naïve adults. The product, marketed in the United States as Complera and in Europe as Eviplera, is the single-tablet regimen for the treatment of HIV and is a fixed-dose combination of the company’s antiretroviral medications, Viread and Emtriva, and Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor, Edurant (rilpivirine). Emtriva: Emtriva is an oral formulation of a nucleoside analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is also available as an oral solution approved as part of combination therapy to treat HIV infection in children. Liver Disease Viread: Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day for the treatment of chronic hepatitis B in adults with compensated and decompensated liver disease. The company licensed the rights to commercialize Viread for the treatment of chronic hepatitis B in Asia and various other territories to GlaxoSmithKline Inc. (GSK). Viread is also approved for the treatment of HIV infection in patients two years of age and older in combination with other antiretroviral agents. Hepsera (adefovir dipivoxil): Hepsera is an oral formulation of a nucleotide analog polymerase inhibitor, dosed once a day to treat chronic hepatitis B in patients 12 years of age and older. The company has licensed to GSK the rights to commercialize Hepsera for the treatment of chronic hepatitis B in Asia, Latin America, and various other territories. Cardiovascular Letairis (ambrisentan): Letairis is an oral formulation of an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. The company has sublicensed to GSK the rights to ambrisentan, marketed by GSK as Volibris (ambrisentan), for PAH in territories outside of the United States. Ranexa (ranolazine): Ranexa is an extended-release tablet for the treatment of chronic angina.
Contact Info
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
www.gilead.com
CEO
Dr. John C. Martin, Ph.D serves as the Chairman and Chief Executive Officer of Gilead Palo Alto, Inc. Dr. Martin served as the President and Chief Executive Officer of Gilead Sciences Inc., from April 1996 to May 2008. He joined Gilead Sciences Inc. in October 1990 as Vice President for Research and Development. From 1984 to 1990, he was employed at Bristol-Myers Squibb, a pharmaceutical company, where he served as a Director of Antiviral Chemistry. He had been with Syntex Corporation from 1978 to 1984. He served as the President of the International Society for Antiviral Research. He has been Chairman of the Board of Gilead Sciences Inc., since May 2008. He served as the Chairman of California Healthcare Institute from February 2009 to 2010. He served as the Chairman of BayBio. Dr. Martin has been a Director of Gen-Probe Inc. since September 20, 2007 and California Healthcare Institute since February 2009. He has been a Director of Gilead Sciences Inc. since April 1996. He serves on the University of Southern California Board of Trustees. He served as a Director of Biotechnology Industry Organization. He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. He served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, he was inducted into the National Academy of Engineering of the National Academies. Dr. Martin holds a PhD in Organic Chemistry from the University of Chicago and MBA in Marketing from Golden Gate University.
Products
www.gilead.com/products
Gilead seeks to develop products that represent significant advancements over current treatments by offering enhanced modes of delivery; more convenient treatment regimens; improved resistance profiles; reduced side effects; and greater efficacy. Through our own internal research and partnerships with universities, medical research institutions and global pharmaceutical leaders, Gilead is rapidly and efficiently making scientific and clinical advancements that raise the standard for new therapeutics that treat life-threatening diseases.
Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need. The company’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS; liver diseases, such as hepatitis B and C; and serious cardiovascular/metabolic and respiratory conditions. It has operations in North America, Europe, and the Asia Pacific. Products HIV/AIDS Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg): Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Atripla is the once-daily single-tablet regimen for HIV intended as a therapy or in combination with other antiretrovirals. It is a fixed-dose combination of the company’s antiretroviral medications, Viread (tenofovir disoproxil fumarate) and Emtriva (emtricitabine), and Bristol Myers-Squibb Company’s (BMS) non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz). The company has collaboration with BMS to develop and commercialize the single-tablet regimen of its Truvada and BMS’s Sustiva in the United States. Under an agreement with Merck & Co., Inc. (Merck), the company promotes and distributes Atripla in 12 countries in Latin America and the Asia Pacific either through Merck or its existing third-party distributors. Truvada (emtricitabine and tenofovir disoproxil fumarate): Truvada is an oral formulation dosed once a day as part of combination therapy to treat HIV infection in adults. It is a fixed-dose combination of the company’s antiretroviral medications, Viread, and Emtriva. Viread: Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in patients two years of age and older. Viread is also approved for the treatment of chronic hepatitis B in adults. Complera/Eviplera: Complera/Eviplera is an oral formulation dosed once a day for the treatment of HIV-1 infection in treatment-naïve adults. The product, marketed in the United States as Complera and in Europe as Eviplera, is the single-tablet regimen for the treatment of HIV and is a fixed-dose combination of the company’s antiretroviral medications, Viread and Emtriva, and Tibotec Pharmaceuticals’ non-nucleoside reverse transcriptase inhibitor, Edurant (rilpivirine). Emtriva: Emtriva is an oral formulation of a nucleoside analog reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. In the United States and Europe, Emtriva is also available as an oral solution approved as part of combination therapy to treat HIV infection in children. Liver Disease Viread: Viread is an oral formulation of a nucleotide analog reverse transcriptase inhibitor, dosed once a day for the treatment of chronic hepatitis B in adults with compensated and decompensated liver disease. The company licensed the rights to commercialize Viread for the treatment of chronic hepatitis B in Asia and various other territories to GlaxoSmithKline Inc. (GSK). Viread is also approved for the treatment of HIV infection in patients two years of age and older in combination with other antiretroviral agents. Hepsera (adefovir dipivoxil): Hepsera is an oral formulation of a nucleotide analog polymerase inhibitor, dosed once a day to treat chronic hepatitis B in patients 12 years of age and older. The company has licensed to GSK the rights to commercialize Hepsera for the treatment of chronic hepatitis B in Asia, Latin America, and various other territories. Cardiovascular Letairis (ambrisentan): Letairis is an oral formulation of an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. The company has sublicensed to GSK the rights to ambrisentan, marketed by GSK as Volibris (ambrisentan), for PAH in territories outside of the United States. Ranexa (ranolazine): Ranexa is an extended-release tablet for the treatment of chronic angina.
Contact Info
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
www.gilead.com
CEO
Dr. John C. Martin, Ph.D serves as the Chairman and Chief Executive Officer of Gilead Palo Alto, Inc. Dr. Martin served as the President and Chief Executive Officer of Gilead Sciences Inc., from April 1996 to May 2008. He joined Gilead Sciences Inc. in October 1990 as Vice President for Research and Development. From 1984 to 1990, he was employed at Bristol-Myers Squibb, a pharmaceutical company, where he served as a Director of Antiviral Chemistry. He had been with Syntex Corporation from 1978 to 1984. He served as the President of the International Society for Antiviral Research. He has been Chairman of the Board of Gilead Sciences Inc., since May 2008. He served as the Chairman of California Healthcare Institute from February 2009 to 2010. He served as the Chairman of BayBio. Dr. Martin has been a Director of Gen-Probe Inc. since September 20, 2007 and California Healthcare Institute since February 2009. He has been a Director of Gilead Sciences Inc. since April 1996. He serves on the University of Southern California Board of Trustees. He served as a Director of Biotechnology Industry Organization. He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. He served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, he was inducted into the National Academy of Engineering of the National Academies. Dr. Martin holds a PhD in Organic Chemistry from the University of Chicago and MBA in Marketing from Golden Gate University.
Products
www.gilead.com/products
Gilead seeks to develop products that represent significant advancements over current treatments by offering enhanced modes of delivery; more convenient treatment regimens; improved resistance profiles; reduced side effects; and greater efficacy. Through our own internal research and partnerships with universities, medical research institutions and global pharmaceutical leaders, Gilead is rapidly and efficiently making scientific and clinical advancements that raise the standard for new therapeutics that treat life-threatening diseases.
Gilead’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular/metabolic and respiratory conditions.